TweetYou have money better spent on a prohormone than just femera only. It wont raise it signifigantly enough to make a difference too much in the way of gains.

Tweet

Originally posted by prolangtum
You have money better spent on a prohormone than just femera only. It wont raise it signifigantly enough to make a difference too much in the way of gains.

agreed.

Tweeti know people have had success with using liquidex while cutting, especially when combined with an NYC to help get rid of estrogen related fat.

Tweetup to a 68% increase in testosterone

TweetIts also going to decrease your IGF-1. 200mg of Ethanate would rasie your test by 3-4 x what femera does, and most wont get good gains off of 200mg of test

Tweetfemara isn't showen to decrease igf-1 levels like arimidex. infact in the studies in women there was no change after 10 weeks

TweetMy thinking was skewed this morning, but it will affect your chloresterol, so i would add some nolva to act as an estrogen in the liver, also, i dont know if this study has any merit since not using steroids but....

I would be more worried about the rebound that Femera will cause.




Clin Breast Cancer 2000 Sep;1 Suppl 1:S68-73

Comparison of in vitro exemestane activity versus other antiaromatase agents.

Soudon J.

Anastrozole, letrozole, and exemestane are the most selective and potent oral antiaromatase agents currently available. However, in vitro and in vivo studies comparing these agents are lacking. Anastrozole and letrozole are reversible, competitive nonsteroidal type II inhibitors, whereas exemestane is an irreversible steroidal type I inactivator. The study was conducted to determine the impact of this characteristic on in vitro residual aromatase activity and protein levels after incubation of JEG-3 cells with aminoglutethimide (a type II inhibitor), anastrozole, exemestane, or letrozole. Aromatase activity was measured after various incubation times with each antiaromatase agent at a concentration 10 times higher than IC50 (concentration giving 50% inhibition). Only exemestane induced a residual inhibition of aromatase activity after its removal, without any change in the aromatase protein level. Aromatase activity increased after preincubation of JEG-3 cells with either aminoglutethimide or anastrozole without any change in the aromatase protein level. The aromatase protein level increased rapidly when cells were incubated with letrozole and aromatase activity inhibition disappeared immediately after removal of the drug. The breakthrough effects in aromatase activity or protein levels observed after treatment with reversible inhibitors may be a factor in therapeutic failure with these agents. These results suggest a possible advantage for exemestane because it is the only clinically available oral irreversible aromatase inactivator.

TweetNow for its affects on HDL and LDL:

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.

Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA.

Department of Internal Medicine, Medical School, University of Ioannina, GR 451 10 Ioannina, Greece. melisaf@cc.uoi.gr

Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis. The drug can significantly reduce the levels of plasma oestrogens, which remain suppressed throughout the treatment. Data are scarce concerning the influence of these drugs on serum lipid levels. In the present study, we evaluated the effects of letrozole on the serum lipid profile in postmenopausal women with breast cancer. A total of 20 patients with breast cancer were treated with letrozole, 2.5 mg once daily. After an overnight fast, serum lipid parameters (total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides, apolipoproteins A1, B and E and lipoprotein (a)) were measured before treatment and at 8 and 16 weeks afterwards. A significant increase in total cholesterol (P=0.05), LDL cholesterol (P<0.01) and apolipoprotein B levels (P=0.05) in the serum, as well as in the atherogenic risk ratios total cholesterol/HDL cholesterol (P<0.005) and LDL cholesterol/HDL cholesterol (P<0.005) was noticed after letrozole treatment. We conclude that letrozole administration in postmenopausal women with breast cancer has an unfavourable effect on the serum lipid profile.

Tweetprolagtum,

bro will adding 50mg clomid ED do the same as adding nolv? and with respect to the heart, lipids, and immune system how serious are we talking here?

Tweetbump. want to avoid nolva, interferes with gh

TweetI would only do it if cutting, to get rid of estrogen fat. but i dont know if ill cut anymore without some as. I hate losing muscle

Tweet

Originally posted by prophet
prolagtum,

bro will adding 50mg clomid ED do the same as adding nolv? and with respect to the heart, lipids, and immune system how serious are we talking here?

clomid would be a good addition,
I woudl give a shot at some prohormones as well, maybe some super one +, just for a possible androgen affect

TweetYour body has a certain level of estrogen for a reason. You are going to screw up your lipid profile big time with this idea. Provided you are old enough a cycle of test would be much easier on your body.